1Massry SG.Metabolic and endocrine complications of the nephrotic syndrome.In:Massry SG Glassock PG.Textbook of enphrology.3th ed. Baltimore.Williams & Wilkines,1995,684-687.
2Gonzalez EA.Martin J.Renal osteodystrophy.pathogenesis and management .Nephrol Dial Transplant.1995.10(Suppl 3):13-21.
3Liach F,Massry SG,On the mechanism of the prevention of secondary hyperparathyroidism in moderate renal insufficiency.J Clin Endocrinol Metab,1985,61:601.
4Galceran T,Martin KJ,Morrissey JJ.et al.Role of 1,25(OH)2D3 on the skeletal resistance to parathyroid hormone,Kidney Int.1987.32:801.
5Delmez AJ.Tinfits C.Grooms P.et al.Parathyroid homone suppression by intravenous 1,25(OH)2D3:A role for iacreased sensitivity to calcium.J Clin Invest,1989.83:1349.
6Hamdy NAT.The spectrum of renal bone disease.Nephrol Dial Transplsant,1995.10:(Suppl.4):14.
9FAIR D E,OGBORN M R,WEILER H A,et al.Dietary soy protein attenuates renal disease progression after 1 and 3 weeks in Han:SPRD-cy
weanling rats[J].Nutr,2004,134: 1504-1507.
10OHGOM M R,NITSCHMANN E,WEILER H A,et al.Modification of polycystic kidney disease and fatty acid status by soy protein diet[J].
Kidney Int,2000,57(1): 159-166.
